Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181

Summary

AGT-181 is a fusion protein containing alpha-L-Iduronidase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously. This study is an extension of a safety and dose ranging study to obtain long term safety and exposure data, as well as information on the biological activity of the investigational drug

Timeline

Start

2015-11

Primary completion

2018-03-19

Completion

2018-08-02

Drugs

Indications